Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Unmet needs in pediatric CML

Michael Mauro • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses unmet needs in pediatric chronic myeloid leukemia (CML), including the need to better define the role of transplantation and available tyrosine kinase inhibitors (TKIs), as well as improving therapy adherence and getting more patients into treatment-free remission (TFR), and better understanding the role of measurable residual disease (MRD) in this patient population. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Novartis, Bristol Myers Squibb, Sun Pharma/Sparc, Takeda; consultancy: Novartis, Bristol Myers Squibb, Takeda, Pfizer.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022
1:42
Managing cardiovascular risks associated with lifelong TKI therapy in CML
Michael Mauro • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals